A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-10-25
Adverse events
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2022-11-22 (study day 17); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-24 (study day 49); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 63); relationship: N
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 78); relationship: N
Grade 1 Vomiting — outcome: UNKNOWN; onset 2023-02-07 (study day 94); relationship: not assessed
Data queries
No data queries.